Literature DB >> 15303078

Management of hyperprolactinemia in patients receiving antipsychotics.

Karen K Miller1.   

Abstract

Hyperprolactinemia is increasingly prevalent in patients with common psychiatric disorders due to increasing prescriptions of antipsychotics, particularly newer atypical neuroleptics, in these patients. However, measurement of prolactin levels is indicated only in symptomatic patients. When hyper-prolactinemia is diagnosed, work-up should include exclusion of other causes of hyperprolactinemia, particularly those that might require treatment. Once such causes have been ruled out, a minority of patients with antipsychotic medication-induced hyperprolactinemia, including those with clinically significant signs and symptoms, will require treatment. When treatment is indicated, specifically when hyperprolactinemia results in amenorrhea in women or testosterone deficiency in men, dopamine agonist therapy is generally not advisable. Hormone-replacement therapy, which involves estrogen/progestogen in women and testosterone in men, can often prevent modification and interruption of successful psychiatric medication regimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15303078     DOI: 10.1017/s1092852900002340

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  3 in total

1.  Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients.

Authors:  Jenn-Huei Renn; Nan-Ping Yang; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2010-02-17       Impact factor: 2.362

2.  Bone mass in schizophrenia and normal populations across different decades of life.

Authors:  Jenn-Huei Renn; Nan-Ping Yang; Ching-Mo Chueh; Chih-Yuan Lin; Tsuo-Hung Lan; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2009-01-01       Impact factor: 2.362

3.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.